High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate
High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate
Flow cytometric expression of bcl-2 protein was analyzed in 90 newly diagnosed acute myeloblastic leukemia (AML) patients using an anti-bcl-2 monoclonal antibody by direct immunofluorescence technique and results were correlated with FAB cytotype, CD34 expression and clinical outcome. Bcl-2 was expressed in all AML cases with different intensity. The mean fluorescence index (MFI), expressed as the ratio of sample mean channel:control mean channel, ranged from 3.0 to 39.5 with a median value of 14. The MFI was significantly higher (P = 0.01) in M0 (20.9) and M1 (18.3) than in M2 (11.7), M3 (12.4), M4 (11.8) and M5 (9.5) cytotypes. In addition, bcl-2 MFI significantly correlated both with CD34 positivity (P = 0.001) and with CD34 MFI (P = 0.01), being CD34 antigen expressed in 65% of patients with a bcl-2 MFI >14, and only in 35% of AML cases with a bcl-2 MFI >14. When bcl-2 intensity expression was correlated with complete remission (CR) rate, a higher MFI was associated with a low CR rate after standard intensive chemotherapy. In particular, CR was achieved in 86% of patients with a bcl-2 MFI <14, but only in 57% of patients with a MFI >14 (P = 0.008). A further decrease of CR rate to 41% was observed in patients in whom a higher bcl-2 MFI was coupled with the presence of CD34 antigen on their blasts. By statistical analysis we also demonstrated that both bcl-2 high MFI (>14) and CD34 expression are independent prognostic factors for achieving CR in AML. These data raise the hypothesis that high values of bcl-2 may confer on myeloid blasts a higher resistance to standard chemotherapy. However, identification of patients with high expression of bcl-2 may be important for a different therapeutic approach.
AML, bcl-2, CR, CD34, MFI
2075-2078
Lauria, F.
735fa868-573e-4a9b-b409-a3316d397c4a
Raspadori, D.
bf030b4a-d671-41d0-bd9f-fac632ed88c8
Rondelli, D.
e7380678-2518-42cb-ae10-d4ef8b900417
Ventura, M. A.
3214389e-be33-4bcd-889d-624370098eae
Fiacchini, M.
32fca2b4-7c75-41e1-a707-a4973240bfa8
Visani, G.
a0b74eed-6389-4cc6-b2c5-9f7e5e160653
Forconi, Francesco
ce9ed873-58cf-4876-bf3a-9ba1d163edc8
Tura, S.
eed48885-b319-4446-a488-c3193a83c2bc
December 1997
Lauria, F.
735fa868-573e-4a9b-b409-a3316d397c4a
Raspadori, D.
bf030b4a-d671-41d0-bd9f-fac632ed88c8
Rondelli, D.
e7380678-2518-42cb-ae10-d4ef8b900417
Ventura, M. A.
3214389e-be33-4bcd-889d-624370098eae
Fiacchini, M.
32fca2b4-7c75-41e1-a707-a4973240bfa8
Visani, G.
a0b74eed-6389-4cc6-b2c5-9f7e5e160653
Forconi, Francesco
ce9ed873-58cf-4876-bf3a-9ba1d163edc8
Tura, S.
eed48885-b319-4446-a488-c3193a83c2bc
Lauria, F., Raspadori, D., Rondelli, D., Ventura, M. A., Fiacchini, M., Visani, G., Forconi, Francesco and Tura, S.
(1997)
High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate.
Leukemia, 11 (12), .
(PMID:9447823)
Abstract
Flow cytometric expression of bcl-2 protein was analyzed in 90 newly diagnosed acute myeloblastic leukemia (AML) patients using an anti-bcl-2 monoclonal antibody by direct immunofluorescence technique and results were correlated with FAB cytotype, CD34 expression and clinical outcome. Bcl-2 was expressed in all AML cases with different intensity. The mean fluorescence index (MFI), expressed as the ratio of sample mean channel:control mean channel, ranged from 3.0 to 39.5 with a median value of 14. The MFI was significantly higher (P = 0.01) in M0 (20.9) and M1 (18.3) than in M2 (11.7), M3 (12.4), M4 (11.8) and M5 (9.5) cytotypes. In addition, bcl-2 MFI significantly correlated both with CD34 positivity (P = 0.001) and with CD34 MFI (P = 0.01), being CD34 antigen expressed in 65% of patients with a bcl-2 MFI >14, and only in 35% of AML cases with a bcl-2 MFI >14. When bcl-2 intensity expression was correlated with complete remission (CR) rate, a higher MFI was associated with a low CR rate after standard intensive chemotherapy. In particular, CR was achieved in 86% of patients with a bcl-2 MFI <14, but only in 57% of patients with a MFI >14 (P = 0.008). A further decrease of CR rate to 41% was observed in patients in whom a higher bcl-2 MFI was coupled with the presence of CD34 antigen on their blasts. By statistical analysis we also demonstrated that both bcl-2 high MFI (>14) and CD34 expression are independent prognostic factors for achieving CR in AML. These data raise the hypothesis that high values of bcl-2 may confer on myeloid blasts a higher resistance to standard chemotherapy. However, identification of patients with high expression of bcl-2 may be important for a different therapeutic approach.
This record has no associated files available for download.
More information
Published date: December 1997
Keywords:
AML, bcl-2, CR, CD34, MFI
Organisations:
Cancer Sciences
Identifiers
Local EPrints ID: 358192
URI: http://eprints.soton.ac.uk/id/eprint/358192
ISSN: 0887-6924
PURE UUID: 6a6f81ae-bc5d-48f1-a8d3-8b55a2572fd3
Catalogue record
Date deposited: 23 Oct 2013 10:50
Last modified: 24 Nov 2022 02:44
Export record
Contributors
Author:
F. Lauria
Author:
D. Raspadori
Author:
D. Rondelli
Author:
M. A. Ventura
Author:
M. Fiacchini
Author:
G. Visani
Author:
S. Tura
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics